Pharma's Market
SPECIAL REPORT
MOST SHARED
- Consumer Sentiment Falters, Despite Job Growth
- Bill Murray's View on the Economy
- Santelli's Morning Bond Report
- Videogame Sales Fell 34 Percent in January
- Steelers' Antonio Brown Spends Super Bowl Week with Twitter Fan Turned BFF
- Home of the Oscars Battles For Kodak Sponsorship
- Greek Police Union Wants to Arrest EU, IMF Officials
- Stocks Stumble as Greek Talks Stall; Vix Soars
- How to Date a Wall Street Man
- Bonus Question Dogs Barclays’ CEO Bob Diamond
- Clint Eastwood ‘Surprised’ by Reaction to Chrysler's ‘Halftime in America’ Ad
- Bulls Check In to Community Health
- Bank of America’s Worst-Case Scenario Gets More Real
- Tesla Unveils First SUV: Model X
- New York Fashion Week Hits the Runway as Colors Pop
- Mulling Buffett's Stock Advice? Get in With REITs: Fund Managers
- LinkedIn Earnings Bode Well for Hiring and Social Media
- Top Five Mistakes to Avoid in Online Dating
- Victor Cruz ‘Understands’ Gisele's Super Bowl Frustrations
- Consumer Sentiment Falters, Despite Job Growth
- Obama to Exempt Religious Employers on Birth Control
- Bonus Bloodbath: Europe Banker Backlash Continues
- Diamond Investing: Why It's Not for the Faint of Heart
- SEC Reaches Settlement in Bear Stearns Fraud Case
- Israel Likely to Bomb Iran This Year: Political Analyst
- The World's Best Beers
- Rep. Bachus Faces Insider Trading Probe: Report
- In Europe, Stagnation as a Way of Life
RSS FEED
Amylin's Byetta Battle
Text Size 
Reporter
Of the 36 companies presenting here at the BioCentury/Thomson Reuters biotech conference, investors are probably most interested in the update from Amylin Pharmaceuticals.
The stock has been on a slide since the FDA and the company disclosed a total of six deaths among diabetics who developed pancreatitis after taking Byetta, the twice-a-day injectable drug from AMLN[AMLN
Loading...
()
] and Eli Lilly[LLY
Loading...
()
].
The CFO Mark Foletta did the presentation to the approximately 100 people in the room. CEO Dan Bradbury didn't make it. Foletta went over the facts that I reported on "Fast Money" when the news broke last week--media coverage that he said has "created some confusion in the marketplace."
"While serious," Foletta said, "it's a condition that is rare and is not new. There's no definitive causal relationship between Byetta and pancreatitis, but a possible association is being explored."
Foletta said he thinks the FDA could change the Byetta label regarding the suspected pancreatitis risk around the time it's expected to make a decision on the approval of Byetta for use as a stand-alone treatment for diabetes. That's supposed to happen, Foletta said, by the end of the year.
He also mentioned--and I think this might be new-- that a "major national insurance carrier" informed the company late last week that among the nearly 40,000 patients it has on Byetta there is "no difference" in the incidence of pancreatitis versus diabetics on other drugs.
One observation, though. Foletta didn't acknowledge the elephant in the room--the pancreatitis-related deaths--until around seven minutes into his formal presentation. In the news biz, that's called burying the lead.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes
